Nelfinavir Mesylate: Orally Bioavailable HIV-1 Protease Inhibitor for Antiviral and Ferroptosis Research

Executive Summary: Nelfinavir Mesylate is a highly selective inhibitor of HIV-1 protease with a Ki of 2.0 nM, blocking viral polyprotein processing and infectious virion formation (APExBIO). It shows in vitro EC₅₀ values as low as 14 nM in HIV-infected CEM cells, with minimal cytotoxicity (TD₅₀ > 5000 nM) (Ofoghi et al., 2025). The compound also inhibits the DDI2 protease, sensitizing cells to ferroptosis via the NFE2L1-UPS axis. Oral bioavailability ranges from 17–47% across preclinical models, supporting translational relevance. Nelfinavir Mesylate is a cornerstone reagent for HIV replication suppression, antiviral drug screening, and mechanistic studies of regulated cell death.

Biological Rationale

HIV-1 protease is essential for the maturation of infectious HIV particles. It cleaves the gag and gag-pol polyproteins into functional components required for viral assembly and infectivity (see related article for workflows). Inhibition of this enzyme disrupts viral replication, leading to non-infectious, immature particles. Nelfinavir Mesylate targets this protease with nanomolar affinity, providing a direct approach for both antiviral intervention and mechanistic research. Additionally, the ubiquitin-proteasome system (UPS) and regulated cell death pathways such as ferroptosis are increasingly recognized as critical modulators of cell fate in viral infections and cancer (Ofoghi et al., 2025). Nelfinavir's dual action on HIV protease and DDI2, a protease regulating NFE2L1 and the UPS, positions it as a unique tool for dissecting these intersecting pathways.

Mechanism of Action of Nelfinavir Mesylate

Nelfinavir Mesylate acts as a competitive, reversible inhibitor of HIV-1 protease. By binding the active site, it prevents cleavage of gag and gag-pol polyproteins. This results in the accumulation of immature, non-infectious viral particles in infected cells (APExBIO). The compound also inhibits the aspartyl protease DDI2 at clinically relevant concentrations, blocking the proteolytic activation of NFE2L1. This impairs the adaptive upregulation of proteasome subunit genes, sensitizing cells to ferroptosis—a regulated, iron-dependent form of cell death characterized by lipid peroxidation (Ofoghi et al., 2025). Nelfinavir Mesylate is orally bioavailable and achieves plasma levels above its antiviral ED₉₅ for over 6 hours in rodent and primate models.

Evidence & Benchmarks

• Nelfinavir Mesylate inhibits HIV-1 protease with a Ki of 2.0 nM, demonstrating high affinity and specificity (APExBIO).
• It suppresses HIV replication in CEM cells infected with HIV-IIIB with an ED₅₀ of 14 nM; minimal cytotoxicity (TD₅₀ > 5000 nM) ensures selectivity (Ofoghi et al., 2025).
• In CEM-SS and MT-2 cell lines, Nelfinavir protects against HIV-1 RF and IIIB-induced cytopathicity with EC₅₀ values of 31–43 nM (see advanced protocols).
• Oral bioavailability is documented as 43% (rat), 47% (dog), 17% (marmoset), and 26% (cynomolgus monkey); plasma levels remain above antiviral thresholds for >6 hours (Ofoghi et al., 2025).
• Nelfinavir inhibits DDI2-mediated NFE2L1 activation, leading to increased ferroptotic sensitivity in cellular models exposed to RSL3 (Ofoghi et al., 2025, Figure 4).

Applications, Limits & Misconceptions

Nelfinavir Mesylate is widely used for:

• HIV protease inhibition assays and antiviral drug development pipelines.
• Mechanistic studies of HIV replication suppression and viral maturation.
• Research on the ubiquitin-proteasome system and protein homeostasis.
• Modeling ferroptosis and caspase-independent cell death in cancer and neurodegeneration (this article extends UPS context).

Common Pitfalls or Misconceptions

• Nelfinavir Mesylate is not directly cytotoxic at research-relevant concentrations; observed cell death effects in ferroptosis models are context-dependent and require co-stressors such as RSL3.
• It does not inhibit all aspartyl proteases; specificity is limited to HIV-1 protease and DDI2 at tested doses (see specificity results).
• Solubility is limited in water; optimal dissolution in DMSO (≥66.4 mg/mL) or ethanol (≥100.4 mg/mL with warming) is required for accurate dosing.
• Long-term storage of solutions is not recommended; prepare fresh aliquots at -20°C for short-term experiments.
• Clinical use in HIV therapy is distinct from research applications; dosages, formulations, and regulatory requirements differ markedly.

Workflow Integration & Parameters

Nelfinavir Mesylate is supplied as a solid by APExBIO (see product page). Standard protocols recommend dissolving the compound at ≥66.4 mg/mL in DMSO and storing aliquots at -20°C. For cell-based assays, working concentrations typically range from 10–100 nM, with cytotoxicity controls above 5,000 nM. For HIV protease inhibition studies, in vitro conditions should include physiological pH (7.4), with controls for buffer composition and viral strain. Ferroptosis assays require co-treatment with GPX4 inhibitors (e.g., RSL3) to observe UPS modulation and cell death sensitivity (this guide shows stepwise integration with cell death models). Plasma and tissue levels in animal models should be monitored for pharmacokinetic validation. Researchers should refer to published protocols for troubleshooting and advanced use-cases (see precision workflows).

Conclusion & Outlook

Nelfinavir Mesylate, available from APExBIO, is a validated, orally bioavailable HIV-1 protease inhibitor with robust applications in antiviral and ferroptosis research. Its dual action—blocking viral polyprotein processing and modulating the DDI2-NFE2L1-UPS axis—positions it as a strategic tool for both virology and cell death modeling. Ongoing studies are expanding its use in oncology, neurodegeneration, and protein homeostasis research. Reliable benchmarks and workflow protocols ensure reproducibility and translational relevance across experimental systems.